| Full text | |
| Author(s): |
Emilio-Silva, Maycon T.
;
Mota, Clarissa M. D.
;
Hiruma-Lima, Clelia A.
;
Antunes-Rodrigues, Jose
;
Carnio, Evelin C.
;
Branco, Luiz G. S.
Total Authors: 6
|
| Document type: | Journal article |
| Source: | Inflammation; v. 40, n. 5, p. 1735-1741, OCT 2017. |
| Web of Science Citations: | 4 |
| Abstract | |
Citral is a mixture of the two monoterpenoid isomers (neral and geranial) widely used as a health-promoting food additive safe for human and animal (approved by the US Food and Drug Administration). In vitro studies have reported on the capability of citral to reduce inflammation. Here, we report antipyretic effects of citral in vivo using the most well-accepted model of sickness syndrome, i.e., systemic administration of) to rats. Citral given by gavage caused no change in control euthermic rats (treated with saline) but blunted most of the assessed parameters related to the sickness syndrome {[}fever (hallmark of infection), plasma cytokines (IL-1 beta, IL-6, and TNF-alpha) release, and prostaglandin E-2 (PGE(2)) synthesis (both peripherally and hypothalamic)]. Moreover, LPS caused a sharp increase in plasma corticosterone levels that was unaltered by citral. These data are consistent with the notion that citral has a corticosterone-independent potent antipyretic effect, acting on the peripheral febrigenic signaling (plasma levels of IL-1 beta, IL-6, TNF-alpha, and PGE(2)), eventually down-modulating hypothalamic PGE(2) production. (AU) | |
| FAPESP's process: | 16/17681-9 - Pathophysiological changes during systemic inflammation |
| Grantee: | Luiz Guilherme de Siqueira Branco |
| Support Opportunities: | Research Projects - Thematic Grants |